New shigella vaccine shows promise in early trial
NCT ID NCT06615375
First seen Feb 14, 2026 · Last updated May 22, 2026 · Updated 13 times
Summary
This study tests a new vaccine called Shigella4V2 to see if it can protect healthy adults from shigellosis, a diarrheal disease caused by Shigella bacteria. About 120 volunteers aged 18-50 will receive either the vaccine or a placebo and then be exposed to the bacteria in a controlled setting. The goal is to see if the vaccine reduces the number of people who get sick.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHIGELLOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Hope Clinic of Emory University
Atlanta, Georgia, 30030, United States
-
Johns Hopkins Center for Immunization Research
Baltimore, Maryland, 21205, United States
Conditions
Explore the condition pages connected to this study.